phathom pharmaceuticals stock
View the latest Phathom Pharmaceuticals Inc. (PHAT) stock price, news, historical charts, analyst ratings and financial information from WSJ. Découvrez comment nous utilisons vos informations dans notre Politique relative à la vie privée et notre Politique relative aux cookies. Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. We believe we can change the status quo of treatment for acid-related disorders. PHAT has been the […] Get the latest Phathom Pharmaceuticals, Inc. PHAT detailed stock quotes, stock … 5 Wall Street analysts have issued ratings and price targets for Phathom Pharmaceuticals in the last 12 months. Looking back to 2 days ago, Phathom Pharmaceuticals Inc (PHAT) priced a 2,250,000 share secondary stock offering at $42.00 per share. Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. Visit a quote page and your recently viewed tickers will be displayed here. QQQ 315.46. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Phathom Pharmaceuticals and the more cash is available to service its debt. Phathom Pharmaceuticals (PHAT) Surges: Stock Moves 6.9% Higher Phathom Pharmaceuticals (PHAT) saw a big move last session, as its shares jumped nearly 7% on … Intraday data delayed at least 15 minutes or per exchange requirements. The stock has a consensus analyst rating of "Hold." It focuses on its vonoprazan product, an oral small molecule potassium-competitive acid blocker. S&P 500 3,943.34. A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PHAT, but not buy more shares or sell existing shares. Illinois R&D Headquarters 2150 E. Lake Cook Road, Suite 800 Buffalo Grove, Illinois 60089 Phathom Pharmaceuticals is working to change the GI treatment landscape and improve the lives of patients with acid-related disorders. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company committed to transforming the treatment landscape and improving the lives of patients suffering from acid-related gastrointestinal (GI) disorders. Time to Start Paying Down Debt, Uncle Sam, 2 Stocks With Earnings Growth Beyond 2021, Bond Vigilantes Are Back, but Unlikely to Cause a New Black Monday for Stocks, Global Emphasis on
Share your opinion and gain insight from other stock traders and investors. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ. Privacy Notice, and
Phathom Pharmaceuticals, Inc. Common Stock (PHAT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)’s share price rose 6.1% during trading on Friday . Phathom Pharmaceuticals currently has 1 sell rating and 4 buy ratings from Wall Street analysts. Cookie Notice (). By using this site you agree to the
Stock analysis for Phathom Pharmaceuticals Inc (PHAT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Find the latest Phathom Pharmaceuticals, Inc. (PHAT) stock discussion in Yahoo Finance's forum. Yahoo fait partie de Verizon Media. Their average twelve-month price target is $53.00, predicting that the stock has a possible upside of 18.30%. Get the latest Phathom Pharmaceuticals Inc (PHAT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI disorders. All quotes are in local exchange time. A high-level overview of Phathom Pharmaceuticals, Inc. (PHAT) stock. Log in to see them here or sign up to get started. Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Director David A. Socks sold 55,000 shares of the company’s stock in a transaction dated Friday, … Copyright © 2021 MarketWatch, Inc. All rights reserved.
Phathom Pharmaceuticals Inc. company facts, information and financial ratios from MarketWatch. The Investor Relations website contains information about Phathom Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. DOW 32,778.64.
Phathom Pharmaceuticals, Inc. Common Stock (PHAT) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. Cool Trend for Trane, Phathom Pharmaceuticals started at outperform with $63 stock price target at BMO Capital, Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and Arcturus Therapeutics (ARCT), Phathom Pharmaceuticals (PHAT) Surges: Stock Moves 6.9% Higher, Needham Issues a Buy Rating on Phathom Pharmaceuticals (PHAT). The stock has a consensus analyst rating of "Buy." There are currently no items in this Watchlist. FLORHAM PARK, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten public offering of 2,250,000 shares of its common stock at a price to the public of $42.00 … Which company executives are buying and selling shares of Phathom Pharmaceuticals (NASDAQ:PHAT) stock? View real-time stock prices and stock quotes for a full financial overview. Informations sur votre appareil et sur votre connexion Internet, y compris votre adresse IP, Navigation et recherche lors de l’utilisation des sites Web et applications Verizon Media. Intraday Data provided by FACTSET and subject to terms of use. The stock had previously closed at $45.12. Have Watchlists? Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.
The stock traded as high as $48.35 and last traded at $47.88. Subscriber Agreement & Terms of Use,
This browser is no longer supported at MarketWatch. Meet Phathom. Phathom Pharmaceuticals Announces Proposed Public Offering of 2,250,000 Shares of Common Stock A "buy" rating indicates that analysts believe PHAT will outperform the market and that investors should add to their positions of Phathom Pharmaceuticals. Create a list of the investments you want to track. Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value , Growth and Safety for Phathom Pharmaceuticals from January 1, 2000. New Jersey Corporate Headquarters 100 Campus Drive, Suite 102 Florham Park, NJ 07932. 3 Best Stocks to Buy That You’ve Probably Never Heard Of. View the latest ratings for PHAT. Something went wrong while loading Watchlist. For the best MarketWatch.com experience, please update to a modern browser.
PHAT | Complete Phathom Pharmaceuticals Inc. stock news by MarketWatch. The Investor Relations website contains information about Phathom Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. Nos partenaires et nous-mêmes stockerons et/ou utiliserons des informations concernant votre appareil, par l’intermédiaire de cookies et de technologies similaires, afin d’afficher des annonces et des contenus personnalisés, de mesurer les audiences et les contenus, d’obtenir des informations sur les audiences et à des fins de développement de produit. Vous pouvez modifier vos choix à tout moment dans vos paramètres de vie privée. The high price target for PHAT … Approximately 155,534 shares changed hands during trading, an increase of 51% from the average daily volume of 103,153 shares.
View today's stock price, news and analysis for Phathom Pharmaceuticals Inc. (PHAT). Phathom is developing vonoprazan, a potassium-competitive acid … Phathom Pharmaceuticals currently has 1 sell rating and 1 buy rating from Wall Street analysts. View Phathom Pharmaceuticals, Inc. PHAT investment & stock information. Phathom Pharmaceuticals earned $1.02 in the third quarter, compared to $1.07 in the year-ago quarter. Pour autoriser Verizon Media et nos partenaires à traiter vos données personnelles, sélectionnez 'J'accepte' ou 'Gérer les paramètres' pour obtenir plus d’informations et pour gérer vos choix. Historical and current end-of-day data provided by FACTSET. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. The stock has a 52-week-high of $64.54 and a 52-week-low of $22.06. PHAT: Get the latest Phathom Pharmaceuticals stock price and detailed information including PHAT news, historical charts and realtime prices. Phathom is an equal opportunity employer that is committed to inclusion and diversity and provides equal opportunity for all applicants without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, veteran status, or other legally protected characteristics. Cleaner Indoor Air Is
View the most recent insider trading activity for PHAT stock at MarketBeat.
Get Phathom Pharmaceuticals Inc (PHAT:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. PHATHOM PHARMACEUTICALS, INC. (+1) 877-742-8466 info@phathompharma.com.